These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 8650156

  • 21. Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells.
    Richon VM, Russo P, Venta-Perez G, Cordon-Cardo C, Rifkind RA, Marks PA.
    Cancer Res; 1997 Jul 01; 57(13):2789-98. PubMed ID: 9205091
    [Abstract] [Full Text] [Related]

  • 22. Potential antitumor agents. 23.(1) Cytotoxic and differentiating activity of compounds related to hexamethylenebisacetamide.
    Andreani A, Rambaldi M, Locatelli A, Andreani F, Lollini PL, Nanni P, Bossa R, Galatulas I.
    Farmaco; 1993 Nov 01; 48(11):1503-13. PubMed ID: 8110363
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Induced differentiation of erythroleukemia cells by hexamethylene bisacetamide: a model for cytodifferentiation of transformed cells.
    Marks PA, Rifkind RA.
    Environ Health Perspect; 1989 Mar 01; 80():181-8. PubMed ID: 2647479
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Dephosphorylation of Vav is associated with the induction of mouse erythroleukemia cell differentiation: effects of orthovanadate and levamisole.
    Scher BM, Wei XJ, Waxman S, Scher W.
    Int J Oncol; 1998 Jun 01; 12(6):1307-13. PubMed ID: 9592191
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division.
    Ramsay RG, Ikeda K, Rifkind RA, Marks PA.
    Proc Natl Acad Sci U S A; 1986 Sep 01; 83(18):6849-53. PubMed ID: 3462732
    [Abstract] [Full Text] [Related]

  • 32. Bcl-XL induction during terminal differentiation of friend erythroleukaemia cells correlates with delay of apoptosis and loss of proliferative capacity but not with haemoglobinization.
    Hafid-Medheb K, Poindessous-Jazat V, Augery-Bourget Y, Hanania N, Robert-Lézénès J.
    Cell Death Differ; 1999 Feb 01; 6(2):166-74. PubMed ID: 10200563
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Differentiation of murine erythroleukemia cells by hexamethylenebisacetamide involves secretion and binding to membranes of a differentiation enhancing factor.
    Sparatore B, Patrone M, Passalacqua M, Melloni E, Pontremoli S.
    Biochem Biophys Res Commun; 1991 Aug 30; 179(1):153-60. PubMed ID: 1883347
    [Abstract] [Full Text] [Related]

  • 36. Alterations in electrophoretic mobility, diaphorase activity, and terminal differentiation induced in murine erythroleukemia lines by differentiating agents.
    Gascoyne PR, Becker FF.
    J Cell Physiol; 1990 Feb 30; 142(2):309-15. PubMed ID: 2303526
    [Abstract] [Full Text] [Related]

  • 37. Nitric oxide-releasing agents and cGMP analogues inhibit murine erythroleukemia cell differentiation and suppress erythroid-specific gene expression: correlation with decreased DNA binding of NF-E2 and altered c-myb mRNA expression.
    Suhasini M, Boss GR, Pascual FE, Pilz RB.
    Cell Growth Differ; 1995 Dec 30; 6(12):1559-66. PubMed ID: 9019161
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Potent cytodifferentiating agents related to hexamethylenebisacetamide.
    Breslow R, Jursic B, Yan ZF, Friedman E, Leng L, Ngo L, Rifkind RA, Marks PA.
    Proc Natl Acad Sci U S A; 1991 Jul 01; 88(13):5542-6. PubMed ID: 2062836
    [Abstract] [Full Text] [Related]

  • 40. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
    Huang L, Pardee AB.
    Mol Med; 2000 Oct 01; 6(10):849-66. PubMed ID: 11126200
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.